MLSS vs. NPCE, CVRX, ZIMV, NYXH, SMTI, AVR, RCEL, LUNG, ELMD, and INGN
Should you be buying Milestone Scientific stock or one of its competitors? The main competitors of Milestone Scientific include NeuroPace (NPCE), CVRx (CVRX), ZimVie (ZIMV), Nyxoah (NYXH), Sanara MedTech (SMTI), Anteris Technologies Global (AVR), AVITA Medical (RCEL), Pulmonx (LUNG), Electromed (ELMD), and Inogen (INGN). These companies are all part of the "medical equipment" industry.
Milestone Scientific vs.
NeuroPace (NASDAQ:NPCE) and Milestone Scientific (NYSE:MLSS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.
NeuroPace received 28 more outperform votes than Milestone Scientific when rated by MarketBeat users. Likewise, 60.00% of users gave NeuroPace an outperform vote while only 2.41% of users gave Milestone Scientific an outperform vote.
NeuroPace currently has a consensus target price of $14.80, suggesting a potential upside of 7.48%. Milestone Scientific has a consensus target price of $1.25, suggesting a potential upside of 20.19%. Given Milestone Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Milestone Scientific is more favorable than NeuroPace.
NeuroPace has a net margin of -36.74% compared to Milestone Scientific's net margin of -52.01%. Milestone Scientific's return on equity of -60.26% beat NeuroPace's return on equity.
78.8% of NeuroPace shares are owned by institutional investors. Comparatively, 5.8% of Milestone Scientific shares are owned by institutional investors. 22.2% of NeuroPace shares are owned by company insiders. Comparatively, 24.8% of Milestone Scientific shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, NeuroPace had 9 more articles in the media than Milestone Scientific. MarketBeat recorded 10 mentions for NeuroPace and 1 mentions for Milestone Scientific. NeuroPace's average media sentiment score of 0.51 beat Milestone Scientific's score of 0.00 indicating that NeuroPace is being referred to more favorably in the media.
Milestone Scientific has lower revenue, but higher earnings than NeuroPace. Milestone Scientific is trading at a lower price-to-earnings ratio than NeuroPace, indicating that it is currently the more affordable of the two stocks.
NeuroPace has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500. Comparatively, Milestone Scientific has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500.
Summary
NeuroPace beats Milestone Scientific on 11 of the 18 factors compared between the two stocks.
Get Milestone Scientific News Delivered to You Automatically
Sign up to receive the latest news and ratings for MLSS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Milestone Scientific Competitors List
Related Companies and Tools
This page (NYSE:MLSS) was last updated on 2/22/2025 by MarketBeat.com Staff
